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OBJECTIVES: There is a growing number of patients on the waiting list for liver 
transplantation, which is currently the only treatment option for patients with 
severe hepatic cirrhosis. The aim of this study was to determine the main factors 
and the impact of the cost of maintaining the cirrhotic patients on the waiting list 
for liver transplant. METHODS: We evaluated 493 patients on the waiting list for 
liver transplantation between the years 2012 and 2014. Of these 139 were called 
to transplantation, 190 remained on the waiting list, 106 were removed by health 
status and 58 died in the list. We used a detailed analysis of micro-costs on the 
waiting list, including clinical data and the cost of materials, drugs, laboratorial 
tests, human resources and hospitalizations. RESULTS: The total cost for patients 
with MELD> 30 was US$10,003.31 ± 7,277.82, MELD 15-29 US$6,585.66 ± 7,526.33 and 
MELD< 15 US$3,201.98 ± 5,001.30 (p < 0.001). The time spent in waiting list was 211 
± 228 days to MELD> 30, 308.17 ± 285.58 to MELD 15-30 and 209.1 ± 208.23 days to 
MELD< 15 (p< 0.001). Hospitalizations occurred in 69.9% of patients with MELD> 30, 
56.4% in MELD 15-30 and 25.8% in MELD< 15 (p< 0.05). The cost of hospitalizations 
was US$9,836.15 ± 7,024.82 in patients with MELD> 30, US$7,442.51 ± 7,792.56 for 
patients with MELD 15-30 and US$6,470.01 ± 6,927.64 to MELD< 15 (p< 0.05), cor-
responding to 68.1%, 60.9% and 51.1% of total expenditures respectively. The cost 
of medications and laboratorial tests for patients with MELD> 30 was US$3,826.31 
± 3,649.99, US$2,480.15 ± 2,996.56 to MELD 15-30 and US$1,271.28 ± 1,987.91 to 
MELD< 15 (p< 0.001). CONCLUSIONS: More severe patients have high-cost on wait-
ing list for liver transplantation. The long time on waiting list, complications that 
lead to hospitalizations, and expensive laboratorial tests and medications cause a 
great financial impact on the public health system.
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OBJECTIVES: New Hepatitis C (HCV) therapies are more effective at treating HCV, 
but come at higher financial costs. Boceprevir has been used with peginterferon 
and ribavirin antivirals for treatment of HCV, achieving sustained virologic response 
(SVR) rates of 65% in clinical trials. Simeprevir, sofosbuvir and combination ledipas-
vir and sofosbuvir are new therapies that have achieved SVR of over 90% in phase III 
clinical trials. Estimating the cost effectiveness of these new therapies is important 
for providers to determine which treatments to adopt in the context of growing cost 
concerns. METHODS: We used Markov simulation to evaluate the cost effectiveness 
of simeprevir, sofosbuvir and combination therapy ledipasvir and sofosbuvir vs. 
the assumed standard of care, boceprevir, among HCV genotype 1 patients over a 
30-year time horizon. Patients progress through stages of the natural history of HCV-
liver fibrosis/cirrhosis, liver transplant and death. Costs, QALYs and outcomes were 
estimated from clinical trials and previously published literature. We calculated 
the incremental net monetary benefit (INMB) between each therapy and standard 
of care. We ran multivariate probabilistic sensitivity analyses (PSA) to quantify the 
uncertainty of the results. RESULTS: New therapies have higher costs and yield 
higher QALYs than boceprevir. Simeprevir at 12 and 24 weeks have the highest INMB 
($85,335.02 and $19,069.64, respectively). Sofosbuvir/ribavirin has a net monetary 
loss compared to the standard of care. The results identify the simeprevir therapy 
to be the most cost effective. PSA reveals simeprevir has the highest likelihood of 
being cost-effective as compared to boceprevir when all inputs are varied simulta-
neously. CONCLUSIONS: Of the new HCV therapies, simeprevir therapy is the best 
value for money when compared to boceprevir. Simeprevir yields the highest QALYs 
of the newer therapy regimens. Further research should focus on patient adherence 
to therapy and associative costs of adverse events to better elucidate value.
PGI18
a cosT-uTIlITy analysIs of bIoloGIcs for moderaTe-To-severe 
crohn’s dIsease: evIdence synThesIs usInG a bayesIan neTwork  
meTa-analysIs
Bounthavong M.1, Bae Y.H.2, Devine B.3, Veenstra D.L.3
1Univer, Seattle, WA, USA, 2Western University of Health Sciences, Pomona, CA, USA, 3University 
of Washington, Seattle, WA, USA
OBJECTIVES: To evaluate the cost-effectiveness of infliximab, adalimumab, certoli-
zumab pegol, and vedolizumab in Moderate-to-Severe Crohn’s disease from a US 
payer perspective with evidence synthesis from a Bayesian network meta-analysis 
(NMA). METHODS: A Markov model was constructed to evaluate the lifetime cost-
effectiveness of biologics and active control (azathioprine) in Crohn’s disease. The 
model used a 3-month cycle with six health states: Moderate-to-Severe, Mild-to-
Severe, Remission, Severe/Fulminant, Post-Surgery, and Death. Transition probabilities 
from Moderate-to-Severe to Remission were synthesized using a Bayesian NMA. Other 
transition probabilities and utility values were derived from the literature. Drug costs 
were based on Medicare Part-B Drug and Biological Average Sales Price Payment files. 
Costs and QALYs were discounted at 3-percent/year. One-way and probabilistic sensi-
tivity analyses (PSA) tested the robustness of the results. Willingness-to-pay threshold 
of $100,000/QALY was considered cost-effective. RESULTS: Transition probabilities 
(Moderate-to-Severe to Remission states) for active control, infliximab, adalimumab, 
certolizumab pegol, and vedolizumab were 0.240, 0.392, 0.483, 0.422, and 0.426, respec-
tively. Utility gained for active control, infliximab, adalimumab, certolizumab pegol, 
and vedolizumab were 17.84, 26.32, 26.35, 26.33, and 26.33 QALYs, respectively. Total 
direct costs for active control, infliximab, adalimumab, certolizumab pegol and vedoli-
zumab were $289,300, $330,700, $425,900, $547,800, and $423,200, respectively. ICER for 
infliximab compared to active control was $4,881/QALY gained. ICER for adalimumab 
GasTroInTesTInal dIsorders – cost studies
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OBJECTIVES: Rifaximin is a minimally absorbed antimicrobial agent that has demon-
strated efficacy for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in 
3 multicenter, randomized, controlled trials. After an initial 2-week course of therapy, 
rifaximin should be considered for repeat treatment only upon recurrence of symp-
toms, in contrast to other IBS treatment options that require chronic administration 
to maintain symptom improvement. The aim of this study was to evaluate the cost of 
adopting rifaximin for treating patients with IBS-D. METHODS: A model was created 
to project the incremental budget impact of adding rifaximin for treating patients 
with IBS-D in the US. The budget impact (2014 dollars) with rifaximin was estimated 
based on a hypothetical health plan with 10,000,000 members and 138,813 treated IBS 
patients receiving antidiarrheals, rifaximin, antispasmodics, alosetron, lubiprostone, 
linaclotide, and tricyclic antidepressants. Drug acquisition and office visit costs were 
applied to estimate the budget impact relative to the current environment over 3 years. 
Uptake of rifaximin was assumed to be 3.5% (year 1), 8.5% (year 2), and 15% (year 3). 
Adverse events and their associated costs were deemed similar between treatments 
and not included. RESULTS: The projected 1-, 2-, and 3-year budget impact of rifaximin 
resulted in annual savings for the health plan of $4,673,829 [per member per month 
(PMPM): $0.04], $11,350,728 (PMPM: $0.09), and $20,030,696 (PMPM: $0.17), totaling 
$36,055,253 over 3 years. Model results were most sensitive to time horizon, unit drug 
costs, and annual doses of alosetron and rifaximin; however, these only impacted the 
magnitude of savings relative to the current environment. Savings were expected when 
rifaximin was administered for up to 2 courses of therapy annually. CONCLUSIONS: 
This model suggests that the treatment of IBS-D with rifaximin, despite its higher unit 
cost, may be associated with savings when used up to twice per year.
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OBJECTIVES: The purpose of this study is to estimate the annual budget impact 
and the cost Per Member per Month of the testing and treatment of hepatitis C in 
the Medi-Cal population using the current testing guidelines METHODS: A budget 
impact analysis was constructed from a state Medicaid perspective to depict the 
financial consequences of implementing the testing and linkage to care guide-
lines recommended by the CDC, AASLD and USPSTF for persons born between 
1945 and 1965. The model included disease testing and drug reimbursement cost. 
Of the 2,277,106 Medi-Cal beneficiaries with birthdates between January 1, 1945 
and December 31, 1964, 1,894,144 are in the Fee for Service and not eligible for 
Medicare. Costs of adverse effects and non-adherence were excluded from the 
analysis. RESULTS: The total cost in one budgetary year of testing and treating the 
birth cohort ranged from between $5,230,285,333.21 and $24,207,966,240.39. The cost 
per member per month increases from $0.55 to between $77.76 and $357 if the birth 
cohort testing recommendation is implemented. CONCLUSIONS: In the base case 
analysis, the birth cohort testing increases the overall cost by over 100% from the 
current risk based testing and treating strategy. Furthermore, sensitivity analysis 
shows a 78% increase from the base case estimates if adjustments are made for 
additional risks in the birth cohort. Treatment of genotype 3 has the biggest budget 
impact followed by the treatment of Genotype1 Interferon ineligible persons. This 
research was conducted without the authorization of the California Department of 
Health Care Services and is not endorsed or validated by the Department.
PGI15
fInancIal ImPacTs of usInG omePrazole oral susPensIon for 
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OBJECTIVES: The objective of the present study was to estimate the financial con-
sequences of using omeprazole immediate-release (IR) oral suspension versus 
intravenous (IV) infusion of pantoprazole for preventing stress-related upper gas-
trointestinal bleeding in critically ill patients from the perspective of the health care 
system. METHODS: An Excel®-based model was developed to compare the cost of 
prevention of upper gastrointestinal bleeding early after intensive care admission using 
the current IV pantoprazole formulation versus omeprazole IR oral suspension. Total 
costs included the cost of acid-suppressive drugs (proton pump inhibitors) and related 
clinical outcomes. Inputs were obtained from a local clinical trial, the Ministry of Health 
database, insurance organizations, hospital and pharmacy registries, the relevant litera-
ture, and expert opinion. The robustness of the input data was investigated by one-way 
sensitivity analysis. During the study period (November 2012 to September 2013), 4,150 
patients were admitted to intensive care units in the different provinces of Iran. The 
model was developed based on the results of a randomized controlled trial in which 
an experimental group and a control group received omeprazole IR oral suspension 
and pantoprazole IV, respectively. RESULTS: According to the proposed model, the cost 
of preventing gastrointestinal bleeding using pantoprazole IV was US$950,000, while 
US$750,000 was spent on omeprazole IR oral suspension. Replacement of IV pantopra-
zole by omeprazole IR oral suspension would lead to an annual cost saving of almost 
US$200,000 (US$4 per member per month) to the health care system. CONCLUSIONS: 
In the present study, a budget impact analysis was performed to assess the financial 
consequences of using omeprazole IR oral suspension in place of pantoprazole IV for 
prevention of upper gastrointestinal bleeding. The better preventive effect of omepra-
zole IR oral suspension when compared with conventional therapy using pantoprazole 
IV was the major reason for the final comparative budgetary savings.
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ombitasvir/dasabuvir) +/- ribavirin compared with Harvoni® (sofosbuvir/ledipas-
vir) in the United States. METHODS: A cost-effectiveness Markov model, based 
on previous HCV models, had 13 health states: 8 disease progression states (F0-
F4, decompensated cirrhosis, hepatocellular carcinoma, and liver transplant), 3 
sustained virologic response states, and 2 mortality states (liver-related and non-
liver-related death). Transition rates were obtained from previous models. Adverse 
events, treatment-related disutility, and efficacy rates were based on phase 3 clini-
cal trials. Baseline patient characteristics were derived from AbbVie 3D phase 3 
clinical trials. Treatment durations were 24 weeks for GT1a experienced cirrhotic 
patients with AbbVie 3D and 8 weeks for 26% of GT1 treatment naïve patients with 
Harvoni. Direct medical costs were based on a systematic literature review and drug 
costs were based on December 2014 Red Book. The model was run over a lifetime 
horizon, discounting at 3% annually. Outcomes were measured in quality-adjusted 
life-years (QALYs). Probabilistic simulation analysis (PSA) was conducted by varying 
all parameters simultaneously. RESULTS: AbbVie 3D resulted in discounted lifetime 
costs per patient of $99,753 and 16.20 QALYs. Harvoni resulted in lifetime costs of 
$108,430 and 16.18 QALYs. With lower costs (-$8,677) and higher QALYs (0.02), AbbVie 
3D dominated Harvoni. AbbVie 3D was superior in 98.4% of PSA simulations when 
QALYs were valued at $100,000 each. CONCLUSIONS: With higher QALYs and lower 
costs, AbbVie 3D dominated Harvoni in GT1-HCV-infected patients.
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OBJECTIVES: Evaluate the cost-effectiveness of universal rotavirus vaccination of 
children below age of five years old in the Philippine setting METHODS: We developed 
an age-stratified dynamic transmission model which compared four settings (baseline 
of no vaccine with 34% exclusive breastfeeding rate (EBR), two-dose monovalent vac-
cine (RV1), three-dose pentavalent vaccine (RV5), and no vaccine with 80% EBR) in the 
Philippine population over a 5-year time horizon. Model parameters such as cost and 
vital statistics were Philippine specific and other parameters such as vaccine efficacy 
and utility were extrapolated from literature. Univariate one-way and multivariate 
probabilities sensitivity analyses were conducted. RESULTS: Compared to baseline, 
the model showed that vaccination could lead to significant reduction in rotaviral 
morbidity and mortality in the 0 to < 5 age group as well as inducing herd immunity in 
the older groups. The incremental cost-effectiveness ratios (ICER) of vaccination ver-
sus baseline from a societal perspective were US$ 13,184/DALY for RV1 and US$ 11,836/
DALY for RV5; these are higher than the the current government cost-effectiveness 
threshold equal to the Philippine GNI per capita of US$ 3,134. Comparing 80% EBR 
to baseline, ICER is US$ 256,417/DALY. ICERs were sensitive to changes in case fatal-
ity, proportion of diarrhea cases due to rotavirus, and vaccine efficacy. The vaccine 
was cost-effective in less than 10% of 5000 Monte Carlo simulations. We estimated 
cost-effective prices of US$ 2.85/dose RV1 and US$ 1.96/dose RV5 which were lower 
than the current price of US$ 9.85/dose RV1 and US$ 6.43/dose RV5. CONCLUSIONS: 
Despite herd immunity benefits, universal vaccination using either RV1 or RV5 is 
unlikely to be cost-effective, at current tendered prices, for the Philippine setting, 
despite the herd immunity benefits. It might be due to comparatively low case-fatality 
rates. Current prices need to be decreased around 70% to achieve cost-effectiveness.
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OBJECTIVES: To assess the cost-effectiveness of daclatasvir plus asunaprevir 
(DCV/ASV) versus peginterferon plus ribavirin (PR) and first generation protease 
inhibitors (PIs) for the treatment of patients with hepatitis C genotype 1b, from the 
perspective of the Chilean public healthcare system. METHODS: A Markov cohort 
model (MONARCH) was built to estimate the expected costs in Chilean pesos (CL$) 
and benefits in quality adjusted life years (QALYs) from aggregated data. Efficacy 
was obtained from a mixed-treatment comparison study and costs were estimated 
from local sources. Utilities were estimated from the literature. A time horizon 
of 46 years and a 3% discount rate was considered for costs and outcomes. Three 
groups of patients were examined: untreated (naïve), partial responders and non-
responders. The ICER in naive patients is presented for a range of DCV/ASV prices. 
Deterministic and probabilistic sensitivity analyses were performed. RESULTS: PIs 
were extendedly dominated by DCV/ASV. In naïve patients the ICER of DCV/ASV 
compared to PR was CL$ 15,696,479/QALY (US$26,160/QALY) at a treatment price 
of CL$48,000,000 (US$79,200); CL$10,751,318/QALY (US$17,918/QALY) at a price 
of CL$36,000,000 (US$60,000); CL$5,950,954/QALY (US$9,918/QALY) at a price of 
CL$24,000,000 (US$40,000); and CL$1,278,270/QALY (US$2,130/QALY) at a price of 
CL$12,000,000 (US$20,000). Whilst the probability of cost-effectiveness at a price 
of CL$36,000,000 was 59%, there is a 45% probability that DCV/ASV dominates PR 
if the price was CL$12,000,000. The ICER for partial responders was CL$6,082,698/
QALY (US$10,137/QALY) and for non-responders CL$6,603,023/QALY (US$11,005/
QALY) at a DCV/ASV price of CL$36,000,000. The ICER was more sensitive to the 
discount rate, efficacy of DCV/ASV and the utility of the sustained viral response 
state in cirrhotic patients CONCLUSIONS: DCV/ASV can be considered cost-
effective at some particular price range. These results provide decision makers 
useful information about the value of incorporating these drugs into the public 
Chilean healthcare system.
compared to infliximab was $3.5 million/QALY. Certolizumab pegol and vedolizumab 
were eliminated by extended dominance. In comparison between infliximab and 
active control, the model was robust to all variables in one-way sensitivity analysis. 
Results comparing adalimumab and infliximab were sensitive to utility values. In 
the PSA, infliximab was 99.6% cost-effective compared to active control; however, 
adalimumab was only 2.6% cost-effective. CONCLUSIONS: Infliximab is cost-effective 
relative to active control, whereas, adalimumab is not when compared to infliximab. 
Other studies have reported varying results which highlights the importance for 
further work in this area.
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OBJECTIVES: Up-to-date estimation of healthcare costs in Ulcerative Colitis (UC) and 
Crohn’s Disease (CD) patients is crucial to inform budgeting and resource allocation 
decisions. Recent introduction of biologic therapies rendered previous cost studies 
with standard therapy obsolete. We sought to determine healthcare costs in a con-
secutive sample of real-world UC and CD patients managed in a specialized facility 
in a tertiary referral center in Israel. METHODS: Data-bases of patients enrolled in an 
ongoing socio-economic study were mined to determine healthcare resource utiliza-
tion during the years 2012 and 2013. This included direct charges for in-patients and 
out-patients, hospitalizations, investigations and medical and surgical treatments. 
Prices were obtained from the Ministry of Health Tariff (12/2014) and expressed as US 
$. Data express costs related to UC and CD patients, excluding any treatments for co-
morbidities. RESULTS: This adult cohort had a mean age of 45.1 ± 17.2 years, with M:F 
ratio 1.04. The mean [median] healthcare cost/patient was: UC, 2012 (n= 273): $1,710 
[$847], 2013 (n= 280): $1,983 [$916]; CD, 2012 (n= 263): $4,231 [$1,450], 2013 (n= 280): 
$4,568 [$1,169]. Between-year differences in costs were not statistically significant. 
Over the two-year period, the major cost drivers in UC were procedures (37.3% of 
costs), consultations (20.4%), biologic medication (17.8%), standard medication (13.5%) 
and hospitalization (9.4%). In CD, the cost drivers were biologic medication (47.4%), 
surgery (13.8%), procedures (12.1%), consultations (11.21%), hospitalization (10.7%) and 
standard medication (4.8%). Mean biologic medication cost/patient in UC increased 
from $293 in 2012 to $352 in 2013; and for CD from $1882 to $2289 respectively. This 
paralleled an increase in the number of patients receiving biologic medication from 
65 in 2012 to 76 in 2013; of these, 81% had CD. CONCLUSIONS: CD patients engender 
much higher healthcare costs that those with UC. Expensive biologic medication 
now becomes the major cost driver in CD, but not UC, patients in the current era.
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OBJECTIVES: Although the high cost burden of chronic hepatitis C (CHC) has been 
described in the literature, there is a lack of data on the assessment of characteristics 
associated with high healthcare utilizers. The purpose of this study was to identify 
demographics and clinical characteristics associated with high healthcare utilizers 
and liver disease progression among CHC patients. METHODS: Health insurance 
claims from 60 self-insured US companies were analyzed (01/2001-03/2013). Adult 
patients with ≥ 2 CHC claims (ICD-9-CM: 070.44 or 070.54), ≥ 6 months of continu-
ous insurance coverage before the first CHC diagnosis and ≥ 36 months after were 
included. Patients with HIV were excluded. Demographics and baseline comorbidi-
ties including CHC- and non-CHC-related conditions were described. Generalized 
estimating equations with logit link for binary outcomes were used to identify the 
most predictive demographics and clinical characteristics of being in the 20% of 
patients with the highest healthcare resource utilization (HRU). Predictive factors of 
liver disease progression were also identified. RESULTS: The mean age of the study 
population (N= 4,898) was 52.4 years and 39.4% were female. Compensated cirrhosis, 
ESLD and both CHC- and non CHC-related comorbidities were strong predictors of 
high healthcare costs, with odds ratios (ORs; 95%CI) for ESLD, ≥ 2 CHC-related, and ≥ 2 
non CHC-related comorbidities of 3.31 (2.80-3.92), 2.78 (2.47-3.12), and 2.18 (1.75-2.71), 
respectively. CHC- and non CHC-related comorbidities were also strong predictors of 
liver disease progression with ORs (95%CI) for ≥ 2 CHC-related and ≥ 2 non CHC-related 
comorbidities of 2.18 (1.83-2.60) and 1.50 (1.14-1.97), respectively. CONCLUSIONS: This 
real-world study suggests that CHC patients with the highest HRU and costs had a 
high level of comorbidity at baseline and that non-CHC conditions are strong predic-
tors of high healthcare costs. Liver disease severity alone does not fully predict high 
consumption of HRU, although when present it is a predictor of high HRU.
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OBJECTIVES: Interferon (INF)-free therapies for the treatment of hepatitis C virus 
(HCV) offer better viral clearance rates and safety profiles than older therapies 
but are priced higher. These therapies have also been shown to have favorable 
cost-effectiveness profiles compared with older therapies; however, the cost-
effectiveness of INF-free regimens relative to each other is unclear. The objective 
of this study was to assess the cost-effectiveness of treating genotype 1 (GT1) HCV 
patients with AbbVie 3D (paritaprevir [developed by AbbVie and Enanta] /ritonavir/
